- Home
- AKA vs ZURA Comparison
AKA vs ZURA Comparison
Compare AKA & ZURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AKA | ZURA |
|---|---|---|
| Founded | 2018 | 2022 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Catalog/Specialty Distribution | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 105.4M | 455.4M |
| IPO Year | 2021 | 2021 |
Fundamental Metrics
Financial Performance| Metric | AKA | ZURA |
|---|---|---|
| Price | $10.76 | $4.09 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 7 |
| Target Price | ★ $19.75 | $18.00 |
| AVG Volume (30 Days) | 1.3K | ★ 1.8M |
| Earning Date | 11-04-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $600,208,000.00 | N/A |
| Revenue This Year | $4.92 | N/A |
| Revenue Next Year | $5.05 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 4.44 | N/A |
| 52 Week Low | $8.42 | $3.15 |
| 52 Week High | $16.38 | $7.25 |
Technical Indicators
Market Signals| Indicator | AKA | ZURA |
|---|---|---|
| Relative Strength Index (RSI) | 48.17 | 36.17 |
| Support Level | $10.73 | $3.90 |
| Resistance Level | $11.48 | $5.87 |
| Average True Range (ATR) | 0.30 | 0.29 |
| MACD | -0.02 | 0.03 |
| Stochastic Oscillator | 60.08 | 34.37 |
Price Performance
Historical ComparisonAbout AKA a.k.a. Brands Holding Corp.
a.k.a. Brands Holding Corp is a portfolio of fashion brands, including Princess Polly, Culture Kings, Petal & Pup, and mnml. Through these brands, the company reaches next-generation consumers who seek fashion inspiration on social media and mainly shop online. The portfolio consists of two women's brands, Princess Polly and Petal & Pup, and two streetwear brands, Culture Kings and mnml. The company generates the majority of its revenue from the United States.
About ZURA Zura Bio Limited
Zura Bio Ltd is a clinical-stage biotechnology company developing novel medicines for patients with autoimmune and inflammatory diseases, including serious and debilitating conditions with unmet medical need. These diseases are often chronic, biologically complex, and difficult to treat, and many patients do not achieve durable disease control with existing therapies. The company has in-licensed three clinical-stage product candidates: Tibulizumab (ZB-106), a bispecific antibody targeting IL-17A and BAFF; Crebankitug (ZB-168), an IgG1 monoclonal antibody targeting IL-7R; and Torudokimab (ZB-880), an IgG4 monoclonal antibody targeting IL-33.